Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 417 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions: - when oral iron preparations are ineffective or cannot be used; - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.

Israeli - Kiingereza - Ministry of Health

cts chemical industries ltd, israel - ferrous as iron iii hydroxide polymaltose compl. - drops - ferrous as iron iii hydroxide polymaltose compl. 50 mg/ml - iron in other combinations - prevention and treatment of iron deficiency anaemia.

Israeli - Kiingereza - Ministry of Health

cts chemical industries ltd, israel - ferrous as iron iii hydroxide polymaltose compl. - syrup - ferrous as iron iii hydroxide polymaltose compl. 50 mg / 5 ml - iron in other combinations - prevention and treatment of iron deficiency anaemia.

Singapoo - Kiingereza - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - hydroxide polymaltose complex eqv iron - syrup - 10mg/ml - hydroxide polymaltose complex eqv iron 50mg/5ml

Filipino - Kiingereza - FDA (Food And Drug Administration)

genpharm, inc.; distributor: genpharm, inc. - iron (as ferric hydroxide polymaltose complex) - syrup - 50mg per 5ml

Filipino - Kiingereza - FDA (Food And Drug Administration)

genpharm, inc.; distributor: genpharm, inc. - iron (as ferric hydroxide polymaltose complex) - syrup (oral drops) - 50mg per ml

Kenya - Kiingereza - Pharmacy and Poisons Board

glenmark pharmaceuticals limited glenmark house, hdo-corporate building, wing – a, - ferric hydroxide polymaltose complex ih - syrup - elemental iron 50mg - antianemic preparations - iron preparations: iron

Israeli - Kiingereza - Ministry of Health

cts ltd - ferrous as iron iii hydroxide sucrose complex - solution for injection - ferrous as iron iii hydroxide sucrose complex 20 mg/ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - venofer is indicated for the treatment of iron deficiency in the following indications:• where there is a clinical need for a rapid iron supply,• in patients who cannot tolerate oral iron therapy or who are non-compliant,• in active inflammatory bowel disease where oral iron preparations are ineffective,• in chronic kidney disease when oral iron preparations are less effective.the diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. hb, serum ferritin, tsat, serum iron, etc.)(hb haemoglobin, tsat transferrin saturation)

Israeli - Kiingereza - Ministry of Health

cts ltd - ferrous as iron iii hydroxide sucrose complex - solution for injection - ferrous as iron iii hydroxide sucrose complex 100 mg / 5 ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - venofer is indicated for the treatment of iron deficiency in the following indications:• where there is a clinical need for a rapid iron supply,• in patients who cannot tolerate oral iron therapy or who are non-compliant,• in active inflammatory bowel disease where oral iron preparations are ineffective,• in chronic kidney disease when oral iron preparations are less effective.the diagnosis of iron deficiency must be based on appropriate laboratory tests (e.g. hb, serum ferritin, tsat, serum iron, etc.)(hb haemoglobin, tsat transferrin saturation)

Marekani - Kiingereza - NLM (National Library of Medicine)

redpharm drug, inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du